<DOC>
	<DOCNO>NCT00093587</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy total-body irradiation donor bone marrow transplant peripheral blood stem cell transplant help stop growth cancer cell . It also help stop patient 's immune system reject donor 's stem cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell . Giving antithymocyte globulin transplant cyclosporine transplant may stop happen . PURPOSE : This randomized clinical trial study well give antithymocyte globulin together cyclosporine work prevent graft-versus-host disease patient undergo chemotherapy without radiation therapy follow donor stem cell transplant acute lymphoblastic leukemia acute myeloid leukemia .</brief_summary>
	<brief_title>Antithymocyte Globulin Cyclosporine Preventing Graft-Versus-Host Disease Patients Undergoing Chemotherapy With Without Radiation Therapy Followed By Donor Stem Cell Transplant Acute Lymphoblastic Leukemia Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare incidence acute graft-vs-host disease ( GVHD ) within first 100 day transplantation patient acute lymphoblastic leukemia acute myeloid leukemia treat myeloablative conditioning regimen comprise cyclophosphamide ( without radiotherapy ) low- vs high-dose anti-thymocyte globulin follow allogeneic HLA-matched related stem cell transplantation cyclosporine . - Compare incidence serious adverse event within first 100 day transplantation patient treat regimen . Secondary - Compare 100-day 6-month survival patient treat regimen . - Compare severity acute GVHD patient treat regimen . - Compare incidence culture-proven infection 100 day 6 month transplantation patient treat regimen . - Compare incidence mucositis , term presence , severity , duration , patient treat regimen . - Compare number day opiate drug within first 30 day transplantation patient treat regimen . - Compare time engraftment patient treat regimen . - Compare incidence hospitalization within first 6 month transplantation , term length initial stay , cumulative total day , number hospitalization , patient treat regimen . - Compare relapse rate time relapse patient treat regimen . - Compare incidence severity chronic GVHD 100 day 6 month transplantation patient treat regimen . OUTLINE : This pilot , randomize , open-label , multicenter study . - Conditioning : All patient receive standard myeloablative-conditioning regimen contains cyclophosphamide IV 2 hour per center regimen , typically day -6 -3 . Patients also undergo total body irradiation OR receive busulfan . - Graft-versus-host disease ( GVHD ) prophylaxis ( part condition ) : Patients randomize 1 2 treatment arm . - Arm I : Patients receive low-dose anti-thymocyte globulin IV 4-8 hour day -3 -1 . - Arm II : Patients receive high-dose anti-thymocyte globulin IV 4-8 hour day -5 -1 . - Allogeneic hematopoietic stem cell transplantation : Patients arm undergo allogeneic peripheral blood stem cell bone marrow transplantation day 0 . - Post-transplantation GVHD prophylaxis : Patients arm receive cyclosporine IV 1-4 hour orally twice daily begin day -1 continue approximately day 60 follow tapering dos day 180 absence GVHD . Patients follow 7 , 14 , 21 , 30 , 100 , 180 day . PROJECTED ACCRUAL : A total 30-60 patient ( 15-30 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Confirmed diagnosis acute myeloid leukemia ( AML ) acute lymphoblastic leukemia In first complete remission second complete remission Secondary AML allow HLAA , B , DRB1 identical relate donor available AND must fully match Class II highresolution molecular HLA typing ( least 4 digit ) Currently receive myeloablative condition regimen include cyclophosphamide All patient center receive conditioning regimen throughout study No fludarabine purine analogue ( e.g . cladribine pentostatin ) part condition regimen No uncontrolled CNS disease PATIENT CHARACTERISTICS : Age 18 55 Performance status ECOG 03 Life expectancy Not specify Hematopoietic Not specify Hepatic Bilirubin &lt; 2 mg/dL ALT and/or AST â‰¤ 3 time normal Renal Creatinine &lt; 2.0 mg/dL OR Creatinine clearance &gt; 50 mL/min Cardiovascular Ejection fraction &gt; 40 % No severe cardiac disease Other Negative pregnancy test Fertile patient must use effective contraception No known contraindication administration rabbit antithymocyte globulin No current drug alcohol abuse No significant medical psychosocial problem unstable disease state ( include , limited , morbid obesity ) would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy No prior concurrent bone marrow transplantation donor positive serology HIV , hepatitis B virus , hepatitis C virus , syphilis No IV immunoglobulin prior engraftment No concurrent ex vivo engineer process graft ( CD34+ enrichment Tcell depletion ) Chemotherapy See Disease Characteristics No prior concurrent methotrexate graftvshost disease prophylaxis Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other More 30 day since prior experimental agent No concurrent investigational agent Enrollment investigational study ( i.e. , antimicrobial agent ) allow life threaten event exhaust treatment modality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2006</verification_date>
	<keyword>graft versus host disease</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
</DOC>